Mycoplasma pneumoniae as an Under- Recognized Agent of Vasculitic Disorders by Mitsuo Narita
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
Mycoplasma pneumoniae  
as an Under- Recognized Agent  
of Vasculitic Disorders 
Mitsuo Narita 
Department of Pediatrics, Sapporo Tokushukai Hospital 
Japan 
1. Introduction 
Mycoplasma pneumoniae, commonly known as a major causative agent of primary atypical 
pneumonia, also causes various kinds of extrapulmonary manifestations involving almost 
all the organs of the human body. The author has classified the extrapulmonary 
manifestations due to M. pneumoniae infection into three categories: the first is a direct type 
in which locally induced cytokines play a role, the second is an indirect type in which 
immune modulation such as autoimmunity plays a role, and the third is a vascular 
occlusion type in which vasculitis and/or thrombosis with or without systemic 
hypercoagulable state plays a role [Narita, 2009, 2010]. This classification system is intended 
to facilitate the understanding of the pathogenesis of extrapulmonary manifestations due to 
M. pneumoniae infection. A diagram depicting the possible ways in which M. pneumoniae can 
induce these three types of extrapulmonary manifestations in relation to the possible 
pathomechanism of pneumonia is shown in Fig 1. Further concrete explanations of each 
mechanism, based on the accumulated in-vitro and in-vivo data, are provided in the 
following sections. Of particular interest is the fact that M. pneumoniae can cause many kinds 
of vasculitic/thrombotic disorders. Mycoplasma pneumoniae may locally affect a vascular wall 
by inducing cytokines and chemokines such as tumor necrosis factor-ǂ and interleukin-8, 
which cause local vasculitic and/or thrombotic vascular occlusion without systemic 
hypercoagulable state. Alternatively, generalized thrombotic vascular occlusion can occur as 
a result of a systemic hypercoagulable state which is in turn a consequence of immune 
modulation leading to the activation of chemical mediators such as complements and fibrin 
D-dimer. 
Although it is already well known that M. pneumoniae can cause a few coagulation 
abnormality disorders such as disseminated intravascular coagulation and stroke, M. 
pneumoniae remains under-recognized as a causative agent for many other 
vasculitic/thrombotic disorders involving various organs of the human body. One reason 
for this must be that the ability of M. pneumoniae to cause vasculitic/thrombotic vascular 
disorders through the local operation of chemical mediators such as cytokines in the absence 
of an apparent systemic hypercoagulable state is not yet widely known. 
In this chapter, the author presents organ-specific and systemic manifestations of 
vasculitic/thrombotic disorders that may be associated with M. pneumoniae infection. 
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Comments are made principally on the etiology by which M. pneumoniae acts as a 
pathogenic agent for each disease. 
 
 
Fig. 1. Pathomechanism of vasculitic/thrombotic disorders caused by M. pneumoniae 
infection (Modified from ref. Narita, 2009. For details, see text). 
2. Mechanism of vasculitic disorders due to M. pneumoniae infection 
2.1 Respiratory infection and hematogenous dissemination 
Mycoplasma pneumoniae is one of the smallest free-living bacteria. It possesses only a minor 
ability to injure respiratory epithelial cells by producing an excess of activated oxygen 
within the infected cells [for review, see Waites & Talkington, 2004]. Recent evidence has 
shown that M. pneumoniae produces the community acquired respiratory distress syndrome 
toxin, but its pathogenic role in human illness still remains to be elucidated [Hardy et al., 
2009; Kannan & Baseman, 2006]. Nevertheless, M. pneumoniae is a major pathogen of 
primary atypical pneumonia as well as a number of extrapulmonary diseases. In this 
context, many previous works have disclosed that the cell membrane of M. pneumoniae 
contains lipoproteins which are potent inducers of cytokines equivalent to bacterial 
lipopolysaccharides [for review, see Sánchez-Vargas & Gómez-Duarte, 2008; Yang et al., 
2004]. Thus it is currently understood that M. pneumoniae pneumonia results from the 
operation of the host immune system, specifically of various kinds of cytokines, rather than 
from direct injury by the organism itself; in other words, M. pneumoniae pneumonia 
develops via immune pathogenesis. 
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Following an initial droplet infection to the lower respiratory tract below the larynx, M. 
pneumoniae begins to propagate on the respiratory surface with ciliated epithelium 
[Krunkosky et al., 2007]. This event facilitates non-specific recognition of the organism by 
the innate immunity of the host through Toll-like receptors 1, 2, and 6, among which Toll-
like receptor 2 plays a major role in initiating intracellular signal transmission [Shimizu, 
2005]. Mycoplasma pneumoniae infection then leads to pneumonia by inducing various kinds 
of cytokines. Among a number of cytokines reported to be associated with the 
pathomechanism of M. pneumoniae pneumonia, the author and coworkers have 
demonstrated that the macrophage-derived cytokines interleukin-18 and interleukin-8 play 
significant roles in the development of pneumonia and are directly related to disease 
severity [Narita et al., 2000, 2001a; Tanaka et al., 2002]. Interleukin-18 is an immune 
regulatory cytokine that functions as an activator of T cells and a subsequent cascade of T 
helper-1 and T helper-2 type cytokines [Tanaka et al., 1996]. Interleulin-8 is an inflammatory 
cytokine and functions as an activator of neutrophils. Several lines of recent in-vitro 
evidence have supported the pathogenic importance of interleukin-8 in the development of 
the clinical picture of M. pneumoniae respiratory infection [Chmura et al., 2008; Sohn et al., 
2005; Yang et al., 2002]. From this perspective, the activation of interleukin-8 by M. 
pneumoniae is one of the key steps in inducing the vasculitic disorders which are the main 
subject of this chapter. 
As regards the presence of pneumonia in relation to the development of extrapulmonary 
diseases, the author and coworkers have found, using polymerase chain reaction 
methodology [Narita et al., 1992], that the genome of M. pneumoniae can be detected more 
frequently in serum from patients without pneumonia than in serum from patients with 
pneumonia [Narita et al., 1996]. This means that pneumonia, which is a consequence of the 
local host immune response occurring on the respiratory surface, plays an important role as 
a kind of fire-wall preventing dissemination of the organism beyond the respiratory tract 
[Cartner et al., 1998; Tanaka et al., 1996]. In this regard, it is important to note that direct-
type extrapulmonary manifestations not infrequently occur in the absence of pneumonia, 
which is a hallmark of mycoplasmal infection. This must be another reason why M. 
pneumoniae is under-recognized as a vasculitic agent: in the absence of pneumonia, 
mycoplasmal infection is not suspected and the patient is not further tested for M. 
pneumoniae serology. 
2.2 Direct mechanisms of vasculitic/thrombotic vascular occlusion 
M. pneumoniae, following its passive transfer into the circulation through the gaps that result 
from direct yet modest injury to the respiratory epithelial cells, is delivered to the distant 
vessels and organs, where it activates various inflammatory substances which then elicit 
vasculitis. These inflammatory substances include interleukin-8, tumor necrosis factor-ǂ, 
macrophage inflammatory peptide-1ǂ [Hardy et al., 2001], intercellular adhesion molecule-1 
[Krunkosky et al., 2007], and regulated upon activation, normal T cells expression and 
secreted [Dakhama et al., 2003], among others. Tumor necrosis factor-ǂ has been observed to 
be induced by M. pneumoniae in vitro from an early period of investigation [Arai et al., 1990; 
Kita et al., 1992]. This cytokine, along with interleukin-8, must play a pivotal role in eliciting 
vasculitic/thrombotic vascular occlusion. In this context, it is of some interest that the 
community acquired respiratory distress syndrome toxin can also induce the production of 
interleukin-8, macrophage inflammatory peptide-1ǂ, and regulated upon activation, normal 
T cells expression and secreted [Hardy et al., 2009]. This toxin also might play some role in 
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the development of vascular disorders. As regards the vascular occlusion-type 
manifestations with direct mechanisms, only occasionally has M. pneumoniae been found by 
culture or by polymerase chain reaction at the site of disease manifestation, typically, in the 
cerebrospinal fluid from patients with central nervous system manifestations. 
2.3 Indirect mechanisms of vasculitic/thrombotic vascular occlusion 
Mycoplasma pneumoniae contains potent immunogenic substances such as glycolipids, 
glycoproteins, and phospholipids within its cytoplasm. Macrophages, following 
phagocytosis of the organism, present these various kinds of mycoplasmal antigens to 
immunocompetent cells causing immune modulation which subsequently elicits 
autoimmunity through these antigens’ molecular mimicry of various human cell 
components [for review, see Yang et al., 2004; Waites & Talkington, 2004]. From the 
perspective of vasculopathy due to M. pneumoniae, the most important aspect of this process 
must be the production of antiphospholipid (anticardiolipin) antibodies [Graw-Panzer et al., 
2009; Nagashima et al., 2010; Snowden et al., 1990; Witmer et al., 2007]. Production of these 
antibodies is well known to occur during the course of autoimmune disorders such as 
systemic lupus erythematosus and to induce hypercoagulable state resulting in 
vasculopathy. As mentioned in the following sections, this ability of M. pneumoniae to 
induce antiphospholipid (anticardiolipin) antibodies is an important key in unraveling the 
indirect pathomechanisms of the vasculitic disorders caused by M. pneumoniae. 
Mycoplasma pneumoniae can also form immune complexes [Biberfeld & Norberg, 1974; 
Mizutani & Mizutani, 1984], which activate complements and platelets, inducing 
coagulopathy, or affect the vascular epithelium, eliciting vasculitis. This ability of M. 
pneumoniae to form immune complexes is another important key to understanding the 
pathomechanisms of the vasculitic disorders caused by M. pneumoniae. To summarize, the 
immune modulations mentioned in this section can in several ways activate platelets, 
complements, and coagulation factors, leading to systemic or local hypercoagulable state. In 
vascular occlusion-type manifestations with indirect mechanisms, M. pneumoniae itself 
cannot typically be found at disease manifestation sites, though this is not the case in disease 
manifestations with direct mechanisms. 
3. Vasculitic/thrombotic disorders due to M. pneumoniae infection 
In Table 1, vascular occlusion-type extrapulmonary manifestations due to M. pneumoniae 
infection are classified according to type of pathomechanism, that is, direct or indirect, 
and according to the organ system which is mainly affected. Kawasaki disease, which 
involves multiple-organs in its manifestations, which include skin rash, lymphadenitis, 
and coronary aneurysm, is included in the cardiovascular category because of its disease 
severity. 
In the following sections, comments are made on how these disorders can be considered 
consequences of M. pneumoniae infection. Since M. pneumoniae is a ubiquitous agent in the 
general population, the possibility of accidental coinfection by M. pneumoniae during the 
course of an unassociated disease should always be taken into account. One must 
remember to distinguish clearly between what M. pneumoniae can do and what it cannot 
do on the basis of its biological abilities. This chapter preferentially includes papers 
reporting vasculitic/thrombotic disorders for which at least one possible pathomechanism 
could reasonably be considered. 
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System Direct mechanism Indirect mechanism 
Cardiovascular  Kawasaki disease, 
Cardiac thrombus, 
Temporal arteritis 
Dermatological  Anaphylactoid purpura, 
Cutaneous vasculitis 
Digestive  Pancreatitis 
Hematological/ 
Hematopoietic 
 Disseminated intravascular 
coagulation, 
Thrombocytopenia, 
Splenic infarct 
Musculoskeletal Arthritis/Arthropathy*, 
Rhabdomyolysis* 
Arthritis/Arthropathy*, 
Rhabdomyolysis* 
Nervous Stroke*, 
Striatal necrosis, 
Psychological disorders, 
Acute disseminated 
encephalomyelitis*, 
Transverse myelitis* 
Stroke*, 
Acute disseminated 
encephalomyelitis*, 
Transverse myelitis*, 
Facial nerve palsy 
Respiratory  Pulmonary embolism 
Sensory Sudden hearing loss  
Urogenital Priapism  
* Mechanisms of both types (direct and indirect) can be postulated for these disorders. 
Table 1. Vasculitic/thrombotic disorders caused by M. pneumoniae infection 
3.1 Cardiovascular system 
Although the existence of a link between acute or chronic M. pneumoniae infection and the 
development of atherosclerosis or coronary heart disease has been a matter for debate in the 
past, a connection between these conditions now seems less likely on the basis of recent 
evidence [Barski et al., 2010; Weiss et al., 2006] and is not included in this chapter. This 
question must be answered with certainty through future research. 
3.1.1 Kawasaki disease 
Kawasaki disease is a febrile illness mainly affecting infants and younger children; it is 
characterized by persistent fever (lasting longer than 5 days) that is nonresponsive to 
antibiotics; bilateral ocular conjunctivitis; redness of the lips, tongue (strawberry tongue) 
and oral cavity; changes in the peripheral extremities (indurative edema and desquamation); 
polymorphous exanthema of the body; and nonpurulent cervical lymph node swelling. It 
has been considered a systemic vasculitic disease with a predilection for the coronary 
arteries, resulting in the development of coronary aneurysm in the most severe cases [for 
review, see Pinna et al., 2008; Wood & Tulloh, 2009]. Though only a very small number of 
cases have been reported from Western countries [Leen & Ling, 1996; Vitale et al., 2010], 
reports of Kawasaki disease in association with M. pneumoniae infection are not infrequent in 
the Japanese literature. Kawasaki disease was first described from Japan [Kawasaki et al., 
1974] and must have an inclination to the Asian ethnicity. Based on this assumption, there 
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may be some inherent difference in genetic background in terms of the link between M. 
pneumoniae infection and susceptibility to Kawasaki disease. Although the pathomechanism 
of Kawasaki disease itself is not yet fully understood, the disease is generally believed to be 
immune-mediated [Pinna et al., 2008; Wood & Tulloh, 2009]. Mycoplasma pneumoniae has 
several arrays for immunomodulation, including cytokine production and T cell/B cell 
activation, and thereby could be a trigger of Kawasaki disease. 
According to the previous case reports, which are mostly from Japan, pneumonia may or 
may not be present in M. pneumoniae infection-associated Kawasaki disease. Thus, even in 
the absence of pneumonia, M. pneumoniae infection must be considered in Kawasaki disease 
particularly when it is encountered during an epidemic of M. pneumoniae infection. 
Coronary arteries are not severely affected in most cases [Leen & Ling, 1996; Narita et al., 
2001a; Sakai et al., 2007]; there has been only one exception, namely, an aneurysm in a single 
case reported from Taiwan [Wang et al., 2001]. 
3.1.2 Cardiac thrombus 
Although it is only a single case to date, a large cardiac thrombus in the right ventricle has 
recently been reported in association with M. pneumoniae infection; it was successfully 
removed through cardiac surgery [Nagashima et al., 2010]. In this case, antiphospholipid 
antibodies (anticardiolipin IgM) were detected in the acute phase of infection but 
disappeared subsequently during convalescence; this observation supports the idea of a 
causal relation between M. pneumoniae infection and the production of antiphospholipid 
antibodies. 
3.1.3 Temporal arteritis 
One epidemiological study in Denmark has shown a close link between distinct peak 
incidences of temporal arteritis and two epidemics of M. pneumoniae infection [Elling et al., 
1996]. Although neither additional case reports nor subsequent further clinical studies seem 
to exist, it is highly possible given the ability of M. pneumoniae to elicit vasculitis that M. 
pneumoniae is also a triggering agent for temporal arteritis. 
3.2 Dermatological system 
3.2.1 Anaphylactoid purpura 
Anaphylactoid purpura, also called allergic purpura or Schönlein-Henoch purpura, is an 
allergic inflammation of the systemic capillary vessels most commonly affecting children, 
which is characterized by nonthrombocytopenic purpura, most remarkably on the bilateral 
lower extremities. This systemic disorder of the capillary vessels is not restricted to the skin; 
rather it also leads to microvascular bleeding manifesting as arthropathy (pain, swelling), 
gastrointestinal symptoms (severe abdominal pain, intestinal bleeding), and renal 
involvement (hematuria, nephritis) etc. It is possible that several infections can elicit these 
allergic reactions, and M. pneumoniae-infection-associated anaphylactoid purpura has 
sporadically been reported [Ghosh & Clements, 1992; Kano et al., 2007]. Considering the 
immunomodulatory properties of M. pneumoniae, it is reasonable to assume that M. 
pneumoniae can cause anaphylactoid purpura. 
3.2.2 Cutaneous vasculitis 
A few cases of cutaneous vasculitis, which is characterized by skin manifestations 
represented by erythematous macropapular rash resembling that observed in erythema 
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multiforme, and by histological findings compatible with vasculitis such as leukocytoclastic 
vasculitis, have been reported in association with M. pneumoniae infection. Interestingly, 
cutaneous vasculitis due to M. pneumoniae was always accompanied by involvement of 
other organs; specifically, retinal vasculitis [Greco et al., 2007], polyarthritis [Perez et al., 
1997], encephalitis [Perez & Montes, 2002], and acute respiratory distress syndrome, 
erythema multiforme, and pancreatitis [Van Bever et al., 1992]. This suggests either that skin 
biopsy, which is essential for the diagnosis of cutaneous vasculitis, is not likely to be 
performed unless other systemic diseases are present, or that cutaneous vasculitis occurs 
inherently as a part of systemic inflammation. In fact, immune complex-mediated activation 
of platelets has been postulated as an etiology for it [Perez & Montes, 2002]. 
3.3 Digestive system 
3.3.1 Pancreatitis 
Pancreatitis, which is often accompanied by other diseases affecting multiple organs 
[Daxböck et al., 2002; Van Bever et al., 1992], has been included among the extrapulmonary 
manifestations of M. pneumoniae infection, but its exact etiology when associated with M. 
pneumoniae infection remains unknown. Although an autoimmune-mediated mechanism 
has been postulated, no concrete evidence supporting this has been obtained. Van Bever et 
al. have suggested that pancreatitis is a consequence of ischemia, that is, persistent shock 
[Van Bever et al., 1992], in which case it could in a broad sense be classified as a vascular 
occlusion (cessation of blood supply)-type extrapulmonary manifestation. 
3.4 Hematological/Hematopoietic system 
3.4.1 Disseminated intravascular coagulation 
Disseminated intravascular coagulation is a representative vascular occlusion-type 
extrapulmonary manifestation [Chryssanthopoulos et al., 2001; De Vos et al., 1974; Koletsky 
& Weinstein, 1980; Kountouras et al., 2003; Maisel et al., 1967; Nilsson et al; 1971]. Although 
the exact mechanism of this disorder when it occurs in association with M. pneumoniae 
infection remains unclear, it must be a consequence of some kind of immune dysregulation, 
perhaps of the release of coagulative substances (i.e. thromboplastin) from damaged lung 
tissue [Maisel et al., 1967; Nilsson et al; 1971], immune complex-mediated activation of 
complements [Chryssanthopoulos et al., 2001; De Vos et al., 1974], or stimulation of 
procoagulant activity among mononuclear cells, which can be induced by lipoglycans of M. 
pneumoniae [Fumarola, 1997]. Among those disorders that arise due to M. pneumoniae 
infection but are fundamentally benign in nature, disseminated intravascular coagulation is 
one of the most serious conditions, as it can lead to multiorgan failure with an occasional 
fatal outcome. 
3.4.2 Thrombocytopenia/Thrombocytopenic purpura 
Enough cases of thrombocytopenia with or without purpura due to M. pneumoniae infection 
have been reported that literature reviews have been published on this subject [Okoli et al., 
2009; Venkatesan et al., 1996]. In one case, isolated thrombocytopenia preceded 
disseminated intravascular coagulation [Chiou et al., 1997]. Several immune-mediated 
etiologies have been considered, including the production of cross-reactive antibodies 
between mycoplasmal antigens and the von Willebrand factor-cleaving metalloprotease [Bar 
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Meir et al., 2000], microvascular platelet thrombosis [Cameron et al., 1992], the production of 
anti-platelet antibodies of some kind [Chen et al., 2004; Venkatesan et al., 1996], and the 
production of autoantibodies to the I antigen, which is expressed not only on erythrocytes 
but also on platelet surfaces [Gursel et al., 2009]. The formation of immune complexes may 
also play a role in the pathomechanism [Veenhoven et al., 1990]. 
Hemophagocytic syndrome, which is characterized by erythrophagocytosis in the bone 
marrow and believed to be a consequence of immune dysregulation, has been reported in 
association with M. pneumoniae infection. Although hemophagocytic syndrome in itself is 
not a vasculitic disease, this disorder predisposes patients to thrombocytopenia through 
thrombophagocytosis with hyperactivation of cytokines [Mizukane et al., 2001] or through 
formation of microthrombi [Bruch et al., 2001]. 
3.4.3 Splenic infarct 
One reported case of splenic infarct occurred during the course of M. pneumoniae infection 
and was associated with the production of antiphospholipid antibodies [Witmer et al., 2007]. 
It must be emphasized that although an autoimmune etiology of this type occurring in 
association with M. pneumoniae infection has been undetectable to date, so that the 
possibility of its existence has been overlooked, such an etiology might underlie several 
thrombotic disorders involving various organs other than the spleen. 
3.5 Musculoskeletal system 
3.5.1 Arthritis/arthropathy 
Arthropathy is frequently encountered during the course of systemic diseases which affect 
the microvasculature of large joints such as anaphylactoid purpura or thrombocytopenic 
purpura, both of which have been mentioned in preceding sections. Apart from this, 
arthritis is a common manifestation of M. pneumoniae infection [Sánchez-Vargas & Gómez-
Duarte, 2008; Waites & Talkington, 2004]. Both monoarthritis and polyarthritis have been 
reported. It is possible that local inflammation elicited by M. pneumoniae through the 
function of cytokines contributes to the disease manifestation affecting the microvasculature 
of joints. 
3.5.2 Rhabdomyolysis 
Rhabdomyolysis is characterized by swollen, painful muscles, elevated serum creatine 
phosphokinase concentrations, hyperkalaemia, hypocalcaemia, and myoglobinuria 
occasionally leading to renal dysfunction. Infections have been included in the panel of 
causes, and M. pneumoniae infection-associated rhabdomyolysis has not infrequently been 
reported [Berger & Wadowksy, 2000; Daxböck et al., 2002; Decaux et al., 1980; Minami et al., 
2003, Rothstein & Kenny, 1979; Weng et al., 2009]. A central role in the development of this 
disease condition has been assigned to tumor necrosis factor-ǂ, which can cause acute 
proteolysis [Knochel, 1993] and which can be induced by M. pneumoniae. Microthrombosis 
has also been identified as a possible contributing factor to disease progression [Knochel, 
1993]. On an interesting related note, rhabdomyolysis due to M. pneumoniae infection has 
occasionally been accompanied by neurological manifestations, in one case with acute 
disseminated encephalomyelitis [Decaux et al., 1980] and in two cases with transverse 
myelitis [Rothstein & Kenny, 1979; Weng et al., 2009]; the etiology of both of these 
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neurological manifestations are presumed to involve vasculopathy (see next section). 
Regardless of whether they have an etiological link with M. pneumoniae-associated 
rhabdomyolysis, these neurological manifestations deserve further study on the assumption 
that there are common pathogenetic factors leading to vascular damage. 
3.6 Nervous system 
Nervous system manifestations are the most frequently reported type of extrapulmonary 
manifestations due to M. pneumoniae infection. Mycoplasma pneumoniae can cause neurologic 
symptoms through vasculitis or vascular occlusion with or without systemic 
hypercoagulative state. With regard to direct mechanisms, the author and coworkers have 
demonstrated that interleukin-6 and interleukin-8 play a significant role in the development 
of neurologic manifestations [Narita et al., 2005]. Moreover, interleukin-6 and interleukin-8 
must be produced intrathecally, because elevated levels of these cytokines were observed in 
acute-phase cerebrospinal fluids without concomitant elevation in sera [Narita et al., 2005]. 
Rather unexpectedly, tumor necrosis factor-ǂ and interferon-Ǆ, which are the key cytokines 
in the development of neurologic diseases associated with bacterial or viral infections, were 
not elevated at all in acute-phase cerebrospinal fluids from patients with M. pneumoniae 
infection. These observations suggest that the pathomechanisms involved in mycoplasmal 
central nervous system manifestations are distinct from those involved in central nervous 
system diseases due to bacterial or viral infections. 
3.6.1 Stroke 
Stroke can occur in children [Fu et al., 1998; Lee et al., 2009; Leonardi et al., 2005; 
Ovetchkine et al., 2002; Parker et al., 1981; Tanir et al., 2006; Visudhiphan et al., 1992] as 
well as in adults [Mulder & Spierings, 1987; Padovan et al., 2001; Senda et al., 2010; 
Snowden et al., 1990; Sočan et al., 2001; Sotgiu et al., 2003]. The middle cerebral arteries 
are most often affected [Fu et al., 1998; Leonardi et al., 2005; Mulder & Spierings, 1987; 
Parker et al., 1981; Senda et al., 2010; Sotgiu et al., 2003], though the internal carotid 
arteries are affected in a few cases [Lee et al., 2009; Tanir et al., 2006; Visudhiphan et al., 
1992]. Although the presence of systemic hypercoagulable state has been reported in a few 
cases, evidenced by disseminated intravascular coagulation [Mulder & Spierings, 1987] or 
by the production of antiphospholipid (anticardiolipin) antibodies [Senda et al., 2010; 
Snowden et al., 1990; Tanir et al., 2006], most cases occur in the absence of such 
conditions. Accordingly, many authors have suggested the presence of local vasculitis 
leading to vascular occlusion as an etiology. In fact, M. pneumoniae was isolated from the 
cerebrospinal fluid of a stroke patient [Sočan et al., 2001], and its genome has been 
detected in the cerebrospinal fluid as well [Padovan et al., 2001], reinforcing the theory of 
a direct mechanism. In addition, a case of multiple stenosis in the entire right Sylvian 
territory, suggesting the presence of vasculitis, has been reported [Ovetchkine et al., 2002]. 
Hematogenously-transferred M. pneumoniae must elicit cerebral vasculitis through the 
operation of inflammatory cytokines such as interleukin-8. 
3.6.2 Striatal necrosis 
Striatal necrosis is a peculiar central nervous system disease characterized by alteration of 
consciousness, extrapyramidal symptoms, and magnetic resonance imaging abnormality of 
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the bilateral striata (the caudate and putamen nuclei). It has been reported in association 
with M. pneumoniae infection [Sakoulas, 2001; Saitoh et al., 1993; van Buiren & Uhl, 2003; 
Zambrino et al., 2000]. Chorea or choreiform movements may be a neurological consequence 
of striatal damage [Al-Mateen et al., 1988; Decaux et al, 1980; Zambrino et al., 2000]. 
Concerning its etiology, it has been reported that no patients with M. pneumoniae-associated 
striatal necrosis have also exhibited systemic hypercoagulative state. A similar disease called 
acute necrotizing encephalopathy affecting the bilateral thalami is believed to stem from 
vascular injury in the absence of a thrombotic mechanism [Mizuguchi et al., 1995], and a few 
cases of bilateral thalamic necrosis strongly resembling acute necrotizing encephalopathy 
have been reported in association with M. pneumoniae infection [Ashtekar et al., 2003; Perez 
et al., 2002]. It can reasonably be postulated that the pathomechanism underlying striatal 
necrosis must be local vasculitis induced by M. pneumoniae through the operation of 
cytokines and chemokines and leading eventually to vascular occlusion. In fact, 
cerebrospinal fluid from a patient with this disease was found to contain the genome of M. 
pneumoniae [Saitoh et al., 1993], which suggested a direct mechanism. Moreover, two 
reported cases of the involuntary movement disorder Tourette syndrome have been 
accompanied by the detectable presence of the M. pneumoniae genome in cerebrospinal fluid 
[Müller et al., 2000]. This strongly suggests that Tourette syndrome associated with M. 
pneumoniae infection is a result of vasculopathy in the basal ganglia resulting from a direct 
type mechanism inducing vascular occlusion. The accumulated evidence strongly suggests a 
vasculitic vascular occlusion mechanism for extrapyramidal diseases with involuntary 
movements as common manifestations. 
3.6.3 Psychological disorders 
Kluver-Bucy syndrome is a rare neurobehavioral syndrome which has been described in 
association with several neurologic disorders that cause destruction or dysfunction of the 
temporal lobe(s). It is characterized by psychic blindness, a strong urge to examine all 
subjects by mouth, and altered sexual behavior, among others. One case has been reported 
in association with M. pneumoniae infection [Auvichayapat et al., 2006]. This disorder was 
originally reported in rhesus monkeys following temporal lobectomy. It can reasonably be 
assumed that the transient interruption of blood supply to the temporal lobe caused by M. 
pneumoniae infection elicits the clinical manifestation of Kluver-Bucy syndrome. 
3.6.4 Acute disseminated encephalomyelitis 
Acute disseminated encephalomyelitis is a life-threatening disease which involves extensive 
lesions spreading over the brain and spinal cord. Because of its diverse distribution of 
affected areas, an indirect mechanism has been postulated, namely, immune complex-
mediated vasculopathy [Behan et al., 1986; Guleria et al., 2005; Gupta et al., 2009]. On the 
other hand, recent studies on patients with acute disseminated encephalomyelitis have 
demonstrated the presence of M. pneumoniae genome in the cerebrospinal fluid 
[Matsumoto et al., 2009; Riedel et al., 2001; Yiş et al., 2008], or the presence of M. 
pneumoniae antigens inside the macrophages in the brain tissue [Stamm et al., 2008]. Thus it 
is highly possible that a direct mechanism, namely, vasculitis as a consequence of cytokine 
activation by M. pneumoniae, is responsible for some instances of acute disseminated 
encephalomyelitis. 
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3.6.5 Transverse myelitis 
As in the case of acute disseminated encephalomyelitis, indirect immunological mechanisms 
such as immune complex-mediated injury leading to vasculopathy have been postulated as 
etiologies for transverse myelitis [Behan et al., 1986; Tsiodras et al., 2006]. As in acute 
disseminated encephalomyelitis, recent studies using polymerase chain reaction have 
reported the successful detection of the genome of M. pneumoniae in cerebrospinal fluid from 
patients with transverse myelitis [Abele-Horn et al., 1998; Goebels et al., 2001]. The 
possibility that vasculitis as a consequence of local cytokine activation at the site of 
inflammation by M. pneumoniae is an etiology of transverse myelitis must not be ignored. 
3.6.6 Facial nerve palsy 
A single case of facial nerve palsy in association with M. pneumoniae infection with 
production of antiphospholipid antibodies has been reported [Snowden et al., 1990]. This 
suggests that vasculopathy of the peripheral vessels resulting from the production of these 
autoantibodies leading to neural damage can be a cause of cranial, and possibly also 
peripheral, nerve palsies. 
3.7 Respiratory system 
3.7.1 Pulmonary embolism 
A few cases of pulmonary embolism have been reported in association with M. pneumoniae 
infection [Graw-Panzer et al., 2009; Sterner and Biberfeld, 1969]. In one case with a 
documented popliteal venous thrombosis, the production of antiphospholipid 
(anticardiolipin) antibodies was demonstrated to be an underlying mechanism [Graw-
Panzer et al., 2009]. As this chapter has repeatedly mentioned, the production of such 
antibodies must play a crucial role in many aspects of M. pneumoniae infection. 
3.8 Sensory system 
3.8.1 Sudden hearing loss 
A possible link between sudden hearing loss and M. pneumoniae infection [García Berrocal et 
al., 2000] is interesting in terms of what it can tell us about pathomechanisms. Sudden 
hearing loss has two major etiologies; direct neural damage as in the case of infection with 
the mumps virus, and vascular damage leading to neural dysfunction. García Berrocal et al. 
have reported that, although the mumps virus is the most frequent of the infectious causes 
implicated in sudden hearing loss, M. pneumoniae is the second. Assuming the vascular 
etiology of sudden hearing loss, it is highly possible that vasculitis or thrombosis caused by 
M. pneumoniae infection occurring within cochlear branches of a labyrinthine artery could 
cause neural dysfunction that would lead to sudden hearing loss. Not a few cases of sudden 
hearing loss due to M. pneumoniae infection might have been overlooked. 
3.9 Urogenital system 
3.9.1 Priapism 
Priapism as a consequence of obstruction of the outflow of blood through the dorsal vein of 
the penis may be a unique, vascular occlusion-type extrapulmonary manifestation of M. 
pneumoniae infection. Although there has only been a single case report [Hirshberg et al., 
1996], it is highly possible that M. pneumoniae can cause this disease, considering the ability 
of M. pneumoniae to elicit vascular occlusion not only within arteries but also within veins. 
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4. Diagnosis and treatment of vasculitic disorders due to M. pneumoniae 
infection 
4.1 Diagnosis of vasculitic disorders due to M. pneumoniae infection 
Diagnosis of vasculitic disorders due to M. pneumoniae infection should be made primarily 
by serologically rather than molecular detection methodologies, for two major reasons. 
Firstly, M. pneumoniae is not always present at the site of vascular damage, except in 
conditions associated with direct vascular occlusion such as striatal necrosis and stroke, 
where a tiny amount of M. pneumoniae may be detected in cerebrospinal fluid by culture 
[Sočan et al., 2001] or by polymerase chain reaction [Padovan et al., 2001; Saitoh et al., 1993]. 
Secondly, respiratory samples such as oropharyngeal swabs, which are routinely utilized for 
molecular detection of infectious organisms, are not always adequate for the diagnosis of 
extrapulmonary manifestations with very little or no respiratory symptoms such as cough 
and sputa. It must be remembered that extrapulmonary manifestations due to M. 
pneumoniae infection occur not infrequently in the absence of pneumonia or even in the 
absence of respiratory symptoms. 
In the serological diagnosis of M. pneumoniae infection, it is important to recall that 
antibodies to M. pneumoniae (that is, both the IgM- and IgG-class antibodies which are 
available for serological testing in routine clinical practice) can persist at detectable levels 
in the serum for several months or even years after the acute phase of infection [Eun et al., 
2008; Lind & Bentzon, 1991]. In addition, given that the human can be infected with M. 
pneumoniae several times during his or her lifetime with or without clinical symptoms, it 
seems likely that there are many asymptomatic antibody carriers in the general 
population [Foy, 1993], assuming the fact that antibody responses are evoked during each 
instance of infection [Eun et al., 2008; Ito et al., 2001; Kung et al., 2007]. Thus, testing 
paired acute- and convalescent- phase sera using quantitative methods such as the 
complement fixation test, the particle agglutination test, and the enzyme-linked 
immunosorbent assay to show a significant increase in antibody titers is required for the 
precise diagnosis of a current, rather than a recent past, M. pneumoniae infection [Gnarpe 
et al., 1992]. Diagnosis by a single high titer of antibodies to M. pneumoniae alone, or by a 
single positive IgM test result alone, would be misleading because either of these tests can 
respond to evidence of a recent past infection and may return positive results when there 
is no current infection. 
4.2 Treatment of vasculitic disorders due to M. pneumoniae infection 
A strategy for the treatment of M. pneumoniae infection-associated vascular disorders has 
unfortunately not yet been established. Therapy is fundamentally palliative and may or may 
not include anticoagulative or fibrinolytic treatment. Treatments specific to particular 
diseases, such as high-dose intravenous immunoglobulin infusions for Kawasaki disease, 
have been administered when indicated. The use of macrolide antibiotics, which have not 
only antibiotic effects against M. pneumoniae but also immunomodulatory effects [for 
review, see Amsden, 2005], is reasonable considering the likelihood of an immune 
pathogenesis of the extrapulmonary manifestations of M. pneumoniae infection. In this 
context, steroid therapy in combination with antibiotic therapy is also recommended, and 
appears promising as a treatment for the extrapulmonary manifestations of M. pneumoniae 
because of its immunomodulatory effects [Cimolai, 2006]; it has been shown to have 
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beneficial effects on experimental respiratory infection by M. pneumoniae [Tagliabue et al., 
2008]. 
The successful practical application of immunomodulatory agents such as steroids or 
immunoglobulins in the treatment of vascular occlusion-type extrapulmonary 
manifestations of M. pneumoniae infection has been reported in not a few instances. In these 
cases, neurological disorders such as acute disseminated encephalomyelitis or transverse 
myelitis and thrombocytopenic disorders such as disseminated intravascular coagulation or 
thrombocytopenic purpura are most often treated by immunomodulatory agents because of 
the severity of these diseases. Some authors have reported that therapy with 
immunomodulatory agents was very effective, while others have reported that the effects 
are uncertain. Although it cannot be expected that immunomodulatory agents will affect 
thrombotic disorders that are already established, it is clear that they must have some 
beneficial effects on vasculitic disorders during ongoing inflammation. Additional 
accumulation of data will be necessary to construct a therapeutic strategy for the treatment 
of vascular occlusion-type extrapulmonary manifestations of M. pneumoniae infection. 
4.3 Prognosis of vasculitic disorders due to M. pneumoniae infection 
Prognosis of vasculitic disorders due to M. pneumoniae infection is variable depending on 
the disease manifestations. While the clinical symptoms of M. pneumoniae infection are 
immune-mediated, and can therefore generally be considered self-limiting toward a 
favorable outcome, some cases with fatal outcomes have been reported. Most of these were 
cases with neurological and hematological manifestations; disseminated intravascular 
coagulation was particularly strongly associated with fatal outcome. Delay in the diagnosis 
of M. pneumoniae infection might be a devastating factor in severe cases. Therefore, it must 
always be recalled that M. pneumoniae infection cause vasculitic disorders even in the 
absence of pneumonia, particularly when these vasculitic disorders are encountered during 
an epidemic of M. pneumoniae infection. 
5. Conclusion 
This chapter has discussed the ability of M. pneumoniae to cause various kinds of vascular 
occlusion-type extrapulmonary manifestations as a consequence of immune modulations 
such as cytokine production, lymphocyte proliferation, and immune complex formation. 
Such cases probably occur far more frequently than they are recognized. These vascular 
diseases may occur in the absence of pneumonia or even in the absence of respiratory 
symptoms, with or without systemic hypercoagulable state. With this in mind, the 
possibility of M. pneumoniae infection must be considered in diagnosing 
vasculitic/thrombotic disorders, particularly when such disorders are encountered during 
an epidemic period or within an endemic region of M. pneumoniae infection. Mycoplasmal 
infections are strictly species-specific. For example, rodents are natural hosts of M. pulmonis 
but not of M. pneumoniae, and although they can serve as a model for respiratory infection 
they do not develop extrapulmonary manifestations. To date, the only versatile animal 
models that permit the study of the extrapulmonary manifestations seen in humans are 
exceptional cases such as chimpanzee models [Barile et al., 1994]. For this reason, the 
continued accumulation of human case reports is crucially important to ensure further 
progress in this field. 
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